Fucoxanthin induces apoptosis in human cervical cancer cell line HeLa via PI3K/Akt pathway

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11261-11267

  Ye, Guoliu ^a,b   Lu, Qin ^c   Zhao, Weidong ^a   Du, Danli ^b   Jin, Lijie ^b   Liu, Yusheng ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b BENGBU MEDICAL COLLEGE   (China)

^c Shanghai Jiao Tong University School of Medicine   (China)

Author keywords

Apoptosis; Cervical cancer; Fucoxanthin; HeLa cell; PI3K Akt pathway

Indexed keywords

ADENOSINE TRIPHOSPHATE; FUCOXANTHIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; XANTHOPHYLL;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; HELA CELL LINE; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; OXYGEN CONSUMPTION; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; UTERINE CERVICAL NEOPLASMS; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HELA CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; OXYGEN CONSUMPTION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; XANTHOPHYLLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84927798583     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2337-7     Document Type: Article

References (40)

1. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R. Molecularly targeted therapies in cervical cancer. A systematic review. Gynecol Oncol. 2012;126:291–303.
2. Gadducci A, Tana R, Cosio S, Cionini L. Treatment options in recurrent cervical cancer (review). Oncol Lett. 2010;1:3–11.
3. Peralta-Zaragoza O, Bermudez-Morales VH, Perez-Plasencia C, Salazar-Leon J, Gomez-Ceron C, Madrid-Marina V. Targeted treatments for cervical cancer: a review. Onco Targets Ther. 2012;5:315–28.
4. Coutte L, Dreyer C, Sablin MP, Faivre S, Raymond E. PI3K-Akt-mTOR pathway and cancer. Bull Cancer. 2012;99:173–80.
5. Ahmad A, Biersack B, Li Y, Kong D, Bao B, Schobert R, et al. Deregulation of PI3K/Akt/mTOR signaling pathways by isoflavones and its implication in cancer treatment. Anticancer Agents Med Chem. 2013;13:1014–24.
6. Moon SH, Kim DK, Cha Y, Jeon I, Song J, Park KS. PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. Int J Oncol. 2013;42:921–8.
7. Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, et al. Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res. 2012;18:1464–71.
8. Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, et al. Phosphatidylinositol 3-kinase inhibition by ly294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res. 2006;12:250–6.
9. Mauro C, Zazzeroni F, Papa S, Bubici C, Franzoso G. The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity. Methods Mol Biol. 2009;512:169–207.
10. Deeb D, Gao X, Dulchavsky SA, Gautam SC. CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells. Anticancer Res. 2007;27:3035–44.
11. Wang L, Guo H, Yang L, Dong L, Lin C, Zhang J, et al. Morusin inhibits human cervical cancer stem cell growth and migration through attenuation of NF-kappaB activity and apoptosis induction. Mol Cell Biochem. 2013;379:7–18.
12. Mahata S, Bharti AC, Shukla S, Tyagi A, Husain SA, Das BC. Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. Mol Cancer. 2011;10:39.
13. Kort WJ, Bijma AM, Hekking IM. Inhibition of tumor metastasis by carrageenan-induced granulomas. Clin Exp Metastasis. 1989;7:117–25.
14. Azuma K, Ishihara T, Nakamoto H, Amaha T, Osaki T, Tsuka T, et al. Effects of oral administration of fucoidan extracted from Cladosiphon okamuranus on tumor growth and survival time in a tumor-bearing mouse model. Mar Drugs. 2012;10:2337–48.
15. Kim KN, Ahn G, Heo SJ, Kang SM, Kang MC, Yang HM, et al. Inhibition of tumor growth in vitro and in vivo by fucoxanthin against melanoma B16F10 cells. Environ Toxicol Pharmacol. 2013;35:39–46.
16. Maeda H, Hosokawa M, Sashima T, Takahashi N, Kawada T, Miyashita K. Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int J Mol Med. 2006;18:147–52.
17. Das SK, Hashimoto T, Shimizu K, Yoshida T, Sakai T, Sowa Y, et al. Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. Biochim Biophys Acta. 2005;1726:328–35.
18. Kim KN, Heo SJ, Yoon WJ, Kang SM, Ahn G, Yi TH, et al. Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-kappaB and MAPKs in lipopolysaccharide-induced raw 264.7 macrophages. Eur J Pharmacol. 2010;649:369–75.
19. Ji Y, Lu G, Chen G, Huang B, Zhang X, Shen K, et al. Microcystin-LR induces apoptosis via NF-kappaB/iNOS pathway in INS-1 cells. Int J Mol Sci. 2011;12:4722–34.
20. Wang Y, Zhu Y, Gao L, Yin H, Xie Z, Wang D, et al. Formononetin attenuates IL-1beta-induced apoptosis and NF-kappaB activation in INS-1 cells. Molecules. 2012;17:10052–64.
21. Zhao H, Xu Z, Qin H, Gao Z, Gao L. miR-30b regulates migration and invasion of human colorectal cancer via SIX1. Biochem J. 2014;460:117–25.
22. Han X, Sun Y, Scott S, Bleich D. Tissue inhibitor of metalloproteinase-1 prevents cytokine-mediated dysfunction and cytotoxicity in pancreatic islets and beta-cells. Diabetes. 2001;50:1047–55.
23. Meng ZX, Nie J, Ling JJ, Sun JX, Zhu YX, Gao L, et al. Activation of liver X receptors inhibits pancreatic islet beta cell proliferation through cell cycle arrest. Diabetologia. 2009;52:125–35.
24. Lu G, Zheng M, Zhu Y, Sha M, Wu Y, Han X. Selection of peptide inhibitor to matrix metalloproteinase-2 using phage display and its effects on pancreatic cancer cell lines PANC-1 and CFPAC-1. Int J Biol Sci. 2012;8:650–62.
25. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797–803.
26. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17:590–603.
27. Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/Akt pathway. Cancer Res. 2012;72:5048–59.
28. Olivier S, Robe P, Bours V. Can nf-kappab be a target for novel and efficient anti-cancer agents? Biochem Pharmacol. 2006;72:1054–68.
29. Lin A, Karin M. Nf-kappab in cancer: a marked target. Semin Cancer Biol. 2003;13:107–14.
30. Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004;206:193–9.
31. Passarella RJ, Zhou L, Phillips JG, Wu H, Hallahan DE, Diaz R. Recombinant peptides as biomarkers for tumor response to molecular targeted therapy. Clin Cancer Res. 2009;15:6421–9.
32. Xue G, Restuccia DF, Lan Q, Hynx D, Dirnhofer S, Hess D, et al. Akt/PKB-mediated phosphorylation of twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-beta signaling axes. Cancer Discov. 2012;2:248–59.
33. Tan J, Yu Q. Molecular mechanisms of tumor resistance to PI3K-mTOR targeted cancer therapy. Chin J Cancer 2013.
34. Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, et al. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2013;138:369–81.
35. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131:2349–59.
36. Joo YH, Jung CK, Sun DI, Park JO, Cho KJ, Kim MS. High-risk human papillomavirus and cervical lymph node metastasis in patients with oropharyngeal cancer. Head Neck. 2012;34:10–4.
37. Hisamatsu T, Mabuchi S, Yoshino K, Fujita M, Enomoto T, Hamasaki T, et al. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer. Int J Gynecol Cancer. 2012;22:623–9.
38. Yan X, Chuda Y, Suzuki M, Nagata T. Fucoxanthin as the major antioxidant in Hijikia fusiformis, a common edible seaweed. Biosci Biotechnol Biochem. 1999;63:605–7.
39. Satomi Y. Fucoxanthin induces gadd45a expression and g1 arrest with SAPK/JNK activation in lncap human prostate cancer cells. Anticancer Res. 2012;32:807–13.
40. Hosokawa M, Kudo M, Maeda H, Kohno H, Tanaka T, Miyashita K. Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARgamma ligand, troglitazone, on colon cancer cells. Biochim Biophys Acta. 2004;1675:113–9.